- Home
- SCYX vs CLIR Comparison
SCYX vs CLIR Comparison
Compare SCYX & CLIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- CLIR
- Stock Information
- Founded
- SCYX 1999
- CLIR 2008
- Country
- SCYX United States
- CLIR United States
- Employees
- SCYX N/A
- CLIR N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- CLIR Industrial Machinery/Components
- Sector
- SCYX Health Care
- CLIR Industrials
- Exchange
- SCYX Nasdaq
- CLIR Nasdaq
- Market Cap
- SCYX 28.5M
- CLIR 32.5M
- IPO Year
- SCYX 2014
- CLIR 2012
- Fundamental
- Price
- SCYX $0.71
- CLIR $0.55
- Analyst Decision
- SCYX
- CLIR Strong Buy
- Analyst Count
- SCYX 0
- CLIR 1
- Target Price
- SCYX N/A
- CLIR $2.00
- AVG Volume (30 Days)
- SCYX 115.9K
- CLIR 49.5K
- Earning Date
- SCYX 08-07-2025
- CLIR 08-13-2025
- Dividend Yield
- SCYX N/A
- CLIR N/A
- EPS Growth
- SCYX N/A
- CLIR N/A
- EPS
- SCYX N/A
- CLIR N/A
- Revenue
- SCYX $2,630,000.00
- CLIR $2,895,000.00
- Revenue This Year
- SCYX $463.61
- CLIR $27.61
- Revenue Next Year
- SCYX $310.80
- CLIR $116.19
- P/E Ratio
- SCYX N/A
- CLIR N/A
- Revenue Growth
- SCYX N/A
- CLIR 10.88
- 52 Week Low
- SCYX $0.66
- CLIR $0.46
- 52 Week High
- SCYX $2.29
- CLIR $1.72
- Technical
- Relative Strength Index (RSI)
- SCYX 40.46
- CLIR 35.66
- Support Level
- SCYX $0.70
- CLIR $0.50
- Resistance Level
- SCYX $0.75
- CLIR $0.60
- Average True Range (ATR)
- SCYX 0.04
- CLIR 0.06
- MACD
- SCYX 0.00
- CLIR -0.01
- Stochastic Oscillator
- SCYX 32.29
- CLIR 13.86
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About CLIR ClearSign Technologies Corporation (DE)
ClearSign Technologies Corp is engaged in providing solutions to some of the pressing productivity, energy efficiency, and pollution problems affecting the energy, oil, and gas production, boiler, and processing industries. It believes that its patented ClearSign Core technology can enhance the performance of combustion systems in a broad range of markets, including the energy (upstream oil production and downstream refining), institutional, commercial, and industrial boiler, chemical, and petrochemical industries. The company offers products that include process burners, boiler burners, flares, and ClearSign Eye.